Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
30.05
+0.36 (1.21%)
At close: Mar 19, 2026, 4:00 PM EDT
29.90
-0.15 (-0.50%)
Pre-market: Mar 20, 2026, 8:48 AM EDT
Edgewise Therapeutics Employees
Edgewise Therapeutics had 146 employees as of December 31, 2025. The number of employees increased by 36 or 32.73% compared to the previous year.
Employees
146
Change
36
Growth
32.73%
Revenue / Employee
n/a
Profits / Employee
-$1,149,281
Market Cap
3.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | 31 | 12 | 63.16% |
| Sep 30, 2021 | 30 | 11 | 57.89% |
| Jun 30, 2021 | 26 | - | - |
| Mar 31, 2021 | 22 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Corcept Therapeutics | 730 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Dyne Therapeutics | 258 |
| Viridian Therapeutics | 252 |
| IDEAYA Biosciences | 145 |
EWTX News
- 10 days ago - Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - PRNewsWire
- 16 days ago - Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 - PRNewsWire
- 17 days ago - Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference - PRNewsWire
- 17 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 22 days ago - Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PRNewsWire
- 6 weeks ago - Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PRNewsWire
- 2 months ago - Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - PRNewsWire